Arena Pharmaceuticals, Inc.  

(Public, NASDAQ:ARNA)   Watch this stock  
Find more results for ARNA
4.19
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 3.26 - 6.59
Open     -
Vol / Avg. 0.00/2.89M
Mkt cap 1.01B
P/E     -
Div/yield     -
EPS -0.26
Shares 242.04M
Beta -0.52
Inst. own 59%
Jul 30, 2015
Q2 2015 Arena Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 12, 2015
Arena Pharmaceuticals Inc Annual Shareholders Meeting - 12:00PM EDT - Add to calendar
Jun 12, 2015
Arena Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 13, 2015
Arena Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Arena Pharmaceuticals Inc Earnings call - Webcast
May 11, 2015
Q1 2015 Arena Pharmaceuticals Inc Earnings Release
Apr 15, 2015
Arena Pharmaceuticals Inc at Needham Healthcare Conference
Mar 2, 2015
Q4 2014 Arena Pharmaceuticals Inc Earnings Call - Webcast
Mar 2, 2015
Q4 2014 Arena Pharmaceuticals Inc Earnings Release
Feb 24, 2015
Arena Pharmaceuticals Inc at RBC Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -198.23% -163.67%
Operating margin -177.42% -284.75%
EBITD margin - -259.97%
Return on average assets -30.52% -19.64%
Return on average equity -110.56% -86.94%
Employees 325 -
CDP Score - -

Address

6154 Nancy Ridge Dr
SAN DIEGO, CA 92121-3223
United States - Map
+1-858-4537200 (Phone)
+1-858-4537210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. The Company’s drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for chronic weight management in adults. The Company also has other drug candidates and compounds at various stages of research and development. APD811 is an orally available agonist of the prostacyclin receptor developed for the treatment of vasospastic diseases. Temanogrel is an orally available inverse agonist of the serotonin 2A receptor indicated for the treatment of thrombotic diseases. APD334 is an orally available agonist of the sphingosine 1-phosphate subtype 1 receptor indicated for the treatment of conditions related to autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid arthritis. APD371 is an orally available agonist of the cannabinoid 2 receptor indicated for the treatment of pain.

Officers and directors

Jack Lief Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert E. Hoffman Chief Financial Officer, Senior Vice President - Finance
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Dominic P. Behan Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Steven W. Spector J.D. Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Craig M. Audet Ph.D. Senior Vice President - Operations and Head of Global Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters
William R. Shanahan Jr., M.D., J.D. Senior Vice President, Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Christine Anna White M.D. Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
Donald D. Belcher Independent Director
Age: 76
Bio & Compensation  - Reuters
Scott H. Bice Independent Director
Age: 68
Bio & Compensation  - Reuters
Harry F. Hixson Jr., Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters